LABCORP HOLDINGS INC. Collaboration to improve access to testing services and the delivery of timely results for patients
BURLINGTON, N.C. , July 11, 2024 -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has entered into a comprehensive strategic collaboration with Naples Comprehensive Healthcare (NCH) in Southwest Florida to manage the daily operations of NCH's inpatient lab operations. Separately, Labcorp will begin to serve as the primary lab for NCH's physician network later this summer.
The new relationship combines important capabilities, experience and technologies from both organizations to enhance access to laboratory services and further the delivery of high-quality care.
"Labcorp is focused on delivering high-quality, cost-effective laboratory testing to health systems, physicians, patients, health plans and the communities we serve," said Lenny Monsour, Senior Vice President of Labcorp's Southeast Division. "We look forward to continuing to work with NCH to realize our shared mission to improve health outcomes for the people of Southwest Florida."
The organizations have been working together to plan and implement a smooth, thoughtful transition that maintains continuity of services for patients, hospitals, clinicians and clients, while providing direct access to the additional capabilities of Labcorp.
This relationship follows other strategic collaborations that Labcorp has established with a range of local and regional health systems that have enhanced services for patients and providers.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA, and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.
SOURCE Labcorp
Media, Kimbrel Arculeo, 336-436-8263, [email protected]; Investors, Christin O'Donnell, 336-436-5076, [email protected]
Attachments
- Original Link
- Permalink
Disclaimer
Labcorp Holdings Inc. published this content on 11 July 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 July 2024 11:50:08 UTC.
